Drug Type Small molecule drug |
Synonyms FOTIVDA, Tivopath, tivozanib hydrochloride monohydrate + [9] |
Mechanism PDGFRβ inhibitors(Platelet-derived growth factor receptor beta inhibitors), VEGFR1 antagonists(Vascular endothelial growth factor receptor 1 antagonists), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (24 Aug 2017), |
Regulation- |
Molecular FormulaC22H22Cl2N4O6 |
InChIKeyRQXMKRRBJITKRN-UHFFFAOYSA-N |
CAS Registry682745-41-1 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Renal Cell Carcinoma | US | 10 Mar 2021 | |
Advanced Renal Cell Carcinoma | EU | 24 Aug 2017 | |
Advanced Renal Cell Carcinoma | IS | 24 Aug 2017 | |
Advanced Renal Cell Carcinoma | LI | 24 Aug 2017 | |
Advanced Renal Cell Carcinoma | NO | 24 Aug 2017 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Wet AMD | Phase 2 | US | 31 Jan 2024 | |
Wet AMD | Phase 2 | JP | 31 Jan 2024 | |
Wet AMD | Phase 2 | AU | 31 Jan 2024 | |
Wet AMD | Phase 2 | KR | 31 Jan 2024 | |
Diabetic macular oedema | Phase 2 | US | 09 Jan 2024 | |
Diabetic macular oedema | Phase 2 | JP | 09 Jan 2024 | |
Diabetic macular oedema | Phase 2 | AU | 09 Jan 2024 | |
Diabetic macular oedema | Phase 2 | KR | 09 Jan 2024 | |
Liver Cancer | Phase 2 | US | - | 11 May 2020 |
Metastatic Renal Cell Carcinoma | Phase 2 | FR | 22 Mar 2017 |
Phase 2 | 272 | yceigtxazw(vhsokpzvrw) = pbaepwdvgk nvhpyjpyvc (fonzgqblek ) View more | Positive | 03 Oct 2023 | |||
Phase 1/2 | 25 | (patients previously treated HCC) | nsfsuosdsr(fynmquhkno) = 24 (96%) patients had at least 1 treatment-emergent adverse event (TEAE) phkjxlpwtn (aahcothirj ) View more | Positive | 24 Jan 2023 | ||
(patients previously treated with atezolizumab and bevacizumab) | |||||||
Phase 3 | 350 | nsfdolpsew(ciwfnisimp) = hokrvmzyam lducyarjwg (scpeefezej ) View more | Positive | 28 Dec 2022 | |||
nsfdolpsew(ciwfnisimp) = sghrslnyny lducyarjwg (scpeefezej ) View more | |||||||
NCT00502307 (ASCO2022) Manual | Phase 2 | 46 | bcitthkoow(lblkfszlsz) = koapncclel xxcieyehsb (piskngrmqy, 125 - 366) View more | Positive | 02 Jun 2022 | ||
Phase 3 | 326 | tfqvqwzrho(kqbjpgbham) = sbvguvvnxz ngwdwuvjod (xdcfaylhgs ) | - | 02 Jun 2022 | |||
Phase 3 | 350 | vusmgydczq(gbyeknhwht): HR = 0.624 (95% CI, 0.49 - 0.79) | Positive | 16 Feb 2022 | |||
Not Applicable | Metastatic Renal Cell Carcinoma First line | 113 | vsqnxzsslq(qzapawbpcd) = AEs of any grade occurred in 77% (≥G3 13%) including fatigue 42% (≥G3 0%), diarrhoea 19% (≥G3 < 1%), mucositis 24% (≥G3 2%), anorexia 12% (≥G3 < 1%); and hypertension 7% (≥G3 2%) borrybasep (unczmvjbhz ) View more | Positive | 16 Feb 2022 | ||
Phase 1/2 | Advanced Hepatocellular Carcinoma First line | 7 | ugvvlgcrsu(yklfodyzvr) = gvcbnzwtcg zdqsxfxzat (ydwxymhrxr ) View more | Positive | 19 Jan 2022 | ||
Phase 3 | 343 | rzdudxgyyr(ljstejnohy) = Patients received 1.5-2x more cycles of TIVO compared to SOR and fewer overall grade ≥3 TRAEs in all age groups and irrespective of prior IO tfgushjpbf (erkiocymks ) View more | Positive | 10 Nov 2021 | |||
Phase 2 | 31 | pqzszbsxdw(mnnhgtfeyz) = qtnatarowg ozfjurokhd (uhfvyofzvh ) View more | Positive | 01 Oct 2021 |